ArticleOncotarget2018

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.

Daniel Richard Gomez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.